ABBV - Revance down 16% as investor day update fails to impress
2023-09-19 10:24:49 ET
More on Revance Therapeutics
- Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
- Revance's FDA Nod: Beauty, Brains, And Balance Sheets
- Revance Therapeutics: PDUFA Catalyst 2023 And Increased Revenues
- Revance wins FDA label expansion for lead product
- Seeking Alpha's Quant Rating on Revance Therapeutics
For further details see:
Revance down 16% as investor day update fails to impress